BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Novato, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $3.2 billion and a profit of $349 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.4 out of ten, 9 of 9 metrics filed: past 7.0 out of ten, present 6.6 out of ten, future 5.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 7.4 out of ten. +12.5% a year over 10 filed years; profitable in 5 of 10. 74th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 4.5 out of ten. Share count grew 1.5% a year. 0% of cash flow returned. Insiders: 5 sales, 0 purchases. 45th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 7.6 out of ten. ROE 6%: 6¢ of profit per shareholder dollar. Leverage 20%: owes 20¢ per asset dollar. 76th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 7.8 out of ten. top 22% of 314 in its family; net margin 10.8%. 78th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 2.6 out of ten. bottom 26% of 315 in its family for leadership; chief executive since 2023. 26th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 5.5 out of ten. top 45% of 272 in its family for room to expand. 55th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 6.3 out of ten. top 37% of 307 in its family for growth drivers. 63rd percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 4.8 out of ten. bottom 49% of 234 in its family for expectations against reality. 49th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-10-06 (on EDGAR). Newest filing: Form 8-K, 2026-10-06. Filings on record since 1999. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: VOXZOGO 29%, VIMIZIM 25%, NAGLAZYME 15%, PALYNZIQ 14%, ALDURAZYME 7%, BRINEURA 6%. As tagged in its annual report (Form 10-K, filed 2026-02-26).
Who runs it
Hardy, Alexander (Chief Executive Officer); Mueller, Brian (EVP, Chief Financial Officer); Friberg, Gregory R (EVP, Chief R&D Officer); Davis, George Eric (EVP, Chief Legal Officer); Hubbard, Cristin (EVP, Chief Commercial Officer); Guyer, Charles Greg (EVP, Chief Technical Officer); Ramchandani, Rashmi Virendra (VP, Chief Accounting Officer); Plenge, Robert M (director); Anderson, Elizabeth M (director); Bodem, Barbara W. (director); and 8 more. 18 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-01.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.